|
Treatment regimen
|
N (n)
|
LS mean (SE)
|
95% CI for LS mean
|
Difference from placebo
|
95% CI for differences
|
|---|
|
Change from baseline at day 85
|
|
Placebo (b.i.d. and t.i.d.)
|
18 (15)
|
−0.90 (0.31)
|
(−1.51, −0.28)
| | |
|
GSK2982772 (b.i.d. and t.i.d.)
|
33 (27)
|
−1.27 (0.23)
|
(−1.73, −0.81)
|
−0.38
|
(−1.15, 0.40)
|
|
Change from baseline at day 85 by treatment regimen
|
|
Placebo (b.i.d.)
|
3 (3)
|
−1.00 (0.72)
|
(−2.45, 0.46)
| | |
|
GSK2982772 (b.i.d.)
|
5 (5)
|
−1.47 (0.56)
|
(−2.60, −0.35)
|
− 0.48
|
(−2.33, 1.37)
|
|
Placebo (t.i.d.)
|
15 (12)
|
−0.87 (0.35)
|
(−1.57, − 0.17)
| | |
|
GSK2982772 (t.i.d.)
|
28 (22)
|
−1.23 (0.26)
|
(−1.75, −0.71)
|
−0.36
|
(− 1.23, 0.52)
|
- b.i.d., twice daily; CI, confidence interval; DAS28-CRP, disease activity score for 28 joints using CRP value; LS mean, least squares mean; MMRM, mixed model repeated measures; t.i.d., three times daily
